Clinical Trial Update: Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating anthracycline-free neoadjuvant chemoimmunotherapy for triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: Medical University of South Carolina | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING